Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date

References

• Abecassis M, Bartlett ST, Collins AJ, et al. Kidney transplantation as primary therapy for end-stage renal disease: A national kidney foundation/kidney disease outcomes quality initiative (NKF/KDOQITM) conference. Clinical Journal of the American Society of Nephrology. 2008;3(2):471–480.
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet. 2011;378(9800):1428–1437.
   PubMed Web of Science ®Google Scholar
• EAU Guidelines. Edn. Presented at the EAU Annual Congress. Milan, Italy. 2021. 978-94-92671-13-4.
   Google Scholar
• Massart A, Pallier A, Pascual J, et al. The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. Nephrol Dial Transplant. 2016;31(6):1002–1013.
   PubMed Web of Science ®Google Scholar
• Mysorekar VV, Eshwarappa M, Lingaraj U. Opportunistic infections in a renal transplant recipient. Infectious Disease Reports. 2012;4(1):e8.
   PubMedGoogle Scholar
• Bamoulid J, Staeck O, Halleck F, et al. Immunosuppression and results in renal transplantation. Eur Urol Suppl. 2016;15(9):415. https://www.sciencedirect.com/science/article/pii/S1569905616300823
   Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(3):S1.Suppl.
   PubMedGoogle Scholar
• Bamoulid J, Staeck O, Halleck F, et al. The need for minimization strategies: Current problems of immunosupp ression. Transpl Int. 2015;28(8):891.
   PubMed Web of Science ®Google Scholar
• Jones-Hughes T, Snowsill T, Haasova M, et al. Immunosuppressive therapy for kidney transplantation in adults: A systematic review and economic model. Health Technol Assess. 2016;20(62):1–594.
   Web of Science ®Google Scholar
• Andrade-Sierra J, Vazquez-Galvan PA, Hernandez-Reyes H, et al. Immunosuppressive minimization strategies in kidney transplantation, organ donation and transplantation - current status and future challenges. IntechOpen. 2018.
   Google Scholar
• Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: A review and perspective of the evidence. Am J Nephrol. 2013;37(6):602–612.
   PubMed Web of Science ®Google Scholar
• Rizzari MD, Suszynski TM, Gillingham KJ, et al. Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol. 2012;7(3):494–503.
   PubMed Web of Science ®Google Scholar
• Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909–1919.
   PubMed Web of Science ®Google Scholar
• Eskandary F, Regele H, Baumann L, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. The Journal of the American Society of Nephrology. 2018;29(2):591–605.
   PubMed Web of Science ®Google Scholar
• Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012;12(5):1133–1145.
   PubMed Web of Science ®Google Scholar
• Cooper JE. Evaluation and treatment of acute rejection in kidney allografts. Clin J Am Soc Nephrol. 2020;15(3):430–438.
   PubMed Web of Science ®Google Scholar
• Mitchell LH, Amer R. The use of basiliximab in solid organ transplantation. Expert Opin Pharmacother. 2002;3(11):1657–1663.
   PubMedGoogle Scholar
• Kapic E, Becic F, Kusturica J. Basiliximab, mechanism of action and pharmacological properties. Med Arh. 2004;58(6):373–376.
   PubMedGoogle Scholar
• Gharekhani A, Entezari-Maleki T, Dashti-Khavidaki S, et al. A review on comparing two commonly used rabbit anti-thymocyte globulins as induction therapy in solid organ transplantation. Expert Opin Biol Ther. 2013;13(9):1299–1313.
   PubMed Web of Science ®Google Scholar
• Bamoulid J, Staeck O, Crépin T, et al. Anti-thymocyte globulins in kidney transplantation: Focus on current indications and long-term immunological side effects. Nephrol Dialysis Transplantation. 2017;32(10):1601–1608.
   PubMed Web of Science ®Google Scholar
• Thomusch O, Wiesener M, Opgenoorth M, et al., Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (harmony): An open-label, multicentre, randomised controlled trial. Lancet. 2017;388(10063): 3006–3016.
   Web of Science ®Google Scholar
• Couvrat-Desvergnes G, Salama A, Le Berre L, et al. Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival. J Clin Invest. 2015;125(12):4655–4665.
   PubMed Web of Science ®Google Scholar
• Bayraktar A, Catma Y, Akyildiz A, et al. Infectious complications of induction therapies in kidney transplantation. Annals of Transplantation. 2019;24:412–417.
   PubMed Web of Science ®Google Scholar
• de Paula MI, Bae S, Shaffer AA, et al. The influence of antithymocyte globulin dose on the incidence of CMV infection in high-risk kidney transplant recipients without pharmacological prophylaxis. Transplantation. 2020;104(10):2139–2147.
   PubMed Web of Science ®Google Scholar
• Song T, Yin S, Li X, et al. Thymoglobulin vs. ATG-fresenius as induction therapy in kidney transplantation: A bayesian network meta-analysis of randomized controlled trials. Front Immunol. 2020;11:457.
   PubMed Web of Science ®Google Scholar
• Atlani M, Sharma RK, Gupta A. Basiliximab induction in renal transplantation. Saudi J Kidney Dis Transpl. 2013;24(3):473–479.
   PubMedGoogle Scholar
• Ponticelli C. Basiliximab: efficacy and safety evaluation in kidney transplantation. Expert Opin Drug Saf. 2014;13(3):373–381.
   PubMed Web of Science ®Google Scholar
• Goumard A, Sautenet B, Bailly E, et al. Increased risk of rejection after basiliximab induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies - a retrospective study. Transpl Int. 2019;32(8):820–830.
   PubMed Web of Science ®Google Scholar
• Dedinská I, Granák K, Vnucák M, et al., Induction therapy with ATG compared with anti-IL2 basiliximab in low-immunologic risk kidney transplant recipients. Transplant Proc. 2019;51(10): 3259–3264.
   PubMed Web of Science ®Google Scholar
• Dhaun N, Kluth DC. Alemtuzumab induction therapy in kidney transplantation. Lancet. 2015;385(9970):770.
   PubMedGoogle Scholar
• 3C Study Collaborative Group, Haynes R, Harden P, Judge P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C study): A randomised trial. Lancet 2014;384(9955):1684–1690.
   PubMed Web of Science ®Google Scholar
• Guthoff M, Berger K, Althaus K, et al. Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients. BMC Nephrol. 2020;21(1):178.
   PubMed Web of Science ®Google Scholar
• Bath NM, Djamali A, Parajuli S, et al. Induction and donor specific antibodies in low immunologic risk kidney transplant recipients. Kidney360. 2020;1(12):1407–1418.
   PubMedGoogle Scholar
• Vo AA, Choi J, Cisneros K, et al., Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014;98(3): 312–319.
   PubMed Web of Science ®Google Scholar
• Kälble F, Süsal C, Pego da Silva L, et al. Living donor kidney transplantation in patients with specific HLA antibodies after desensitization with immunoadsorption. Front Med (Lausanne). 2021;8:781491.
   PubMed Web of Science ®Google Scholar
• Naciri Bennani H, Daligault M, Noble J, et al. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation. J Clin Apher. 2021;36(4):584–594.
   PubMed Web of Science ®Google Scholar
• Puliyanda DP, Jordan SC, Kim IK, et al. Use of rituximab for persistent EBV DNAemia, and its effect on donor-specific antibody development in pediatric renal transplant recipients: a case series. Pediatr Transplant. 2021;25(8):e14113.
   PubMed Web of Science ®Google Scholar
• Winstedt L, Järnum S, Nordahl EA, et al. Complete removal of extracellular igg antibodies in a randomized dose-escalation phase i study with the bacterial enzyme IdeS–a novel therapeutic opportunity. PLoS One. 2015;10(7):e0132011.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Legendre C, Desai NM, et al. Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: Results of an international phase 2 trial (Highdes). Transplantation. 2021;105(8):1808–1817.
   PubMed Web of Science ®Google Scholar
• Huang E, Maldonado AQ, Kjellman C, et al. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. Am J Transplant. 2022;22(3):691–697.
   PubMed Web of Science ®Google Scholar
• Kidney disease: Improving global outcomes (KDIGO) transplant work group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;3:1–155.
   Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al., ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25): 2562–2575.
   PubMed Web of Science ®Google Scholar
• Azarfar A, Ravanshad Y, Mehrad-Majd H, et al. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: an updated systematic review and metaanalysis. Saudi Journal of Kidney Diseases and Transplantation. 2018;29(6):1376–1385.
   PubMed Web of Science ®Google Scholar
• Ong PW, Kee T, Ho QY. Impact of tacrolimus versus cyclosporine on one-year renal transplant outcomes: a single-centre retrospective cohort study. Proc Singapore Healthcare. 2020;29(4):217–222.
   Web of Science ®Google Scholar
• Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs. 2004;64(18):2047–2073.
   PubMed Web of Science ®Google Scholar
• Sapir-Pichhadze R, Wang Y, Famure O, et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85(6):1404–1411.
   PubMed Web of Science ®Google Scholar
• Krämer BK, Albano L, Banas B, et al. Efficacy of prolonged- and immediate-release tacrolimus in kidney transplantation: A pooled analysis of two large, randomized, controlled trials. Transplant Proc. 2017;49(9):2040–2049.
   PubMed Web of Science ®Google Scholar
• van Hooff JP, Alloway RR, Trunecka P, et al. Four years experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant. 2011;25(1):1e12.
   Web of Science ®Google Scholar
• Guirado L, Cantarell C, Franco A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant. 2011;11(9):1965–1971.
   PubMed Web of Science ®Google Scholar
• Guirado L, Burgos D, Cantarell C, et al. Medium-term renal function in a large cohort of stable kidney transplant recipients converted from twice-daily to once-daily tacrolimus. Transplant Direct. 2015;1(7):e24.
   PubMedGoogle Scholar
• Sommerer C, Suwelack B, Dragun D, et al. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int. 2019;96(1):231–244.
   PubMed Web of Science ®Google Scholar
• Pascual J, Berger SP, Witzke O, et al. TRANSFORM investigators. everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29(7):1979–1991.
   PubMed Web of Science ®Google Scholar
• Qazi Y, Shaffer D, Kaplan B, et al. Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant. 2017;17(5):1358–1369.
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Pascual J, Viklicky O, et al., TRANSFORM investigators. safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. 2019;103(9): 1953–1963.
   PubMed Web of Science ®Google Scholar
• Berger SP, Sommerer C, Witzke O, et al. TRANSFORM investigators. Two-year outcomes in de novo renal transplant recipients receiving everolimus facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant. 2019;19(11):3018–3034.
   PubMed Web of Science ®Google Scholar
• Salvadori M, Bertoni E. Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant. 2013;3(2):7–25.
   PubMedGoogle Scholar
• Noble J, Jouve T, Janbon B, et al. Belatacept in kidney transplantation and its limitations. Expert Rev Clin Immunol. 2019;15(4):359–367.
   PubMed Web of Science ®Google Scholar
• Wojciechowski D, Vincenti F. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept. Curr Opin Organ Transplant. 2010;15(6):697–702.
   PubMed Web of Science ®Google Scholar
• Melvin G, Sandhiya S, Subraja K. Belatacept: a worthy alternative to cyclosporine? J Pharmacol Pharmacother. 2012;3(1):90–92.
   PubMedGoogle Scholar
• Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. Belatacept Study Group. N Engl J Med. 2005;353(8):770–781.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21(9):1587–1596.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535–546.
   PubMed Web of Science ®Google Scholar
• Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547–557.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012;12(1):210–217.
   PubMed Web of Science ®Google Scholar
• Pestana JO, Grinyo JM, Vanrenterghem Y, et al. A: three-year outcomes from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12(3):630–639.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374(4):333–343.
   PubMed Web of Science ®Google Scholar
• Durrbach A, Pestana JM, Florman S, et al. Long-term outcomes in belatacept versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant. 2016;16(11):3192–3201.
   PubMed Web of Science ®Google Scholar
• Archdeacon P, Dixon C, Belen O, et al. Summary of the US FDA approval of belatacept. Am J Transplant. 2012;12(3):554–562.
   PubMed Web of Science ®Google Scholar
• Xia T, Zhu S, Wen Y, et al. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: A systematic review and meta-analysis. Drug Des Devel Ther. 2018;12:417–428.
   PubMed Web of Science ®Google Scholar
• Morel A, Hoisnard L, Dudreuilh C, et al. Three-year outcomes in kidney transplant recipients switched from calcineurin inhibitor-based regimens to belatacept as a rescue therapy. Transpl Int. 2022;35:10228.
   PubMed Web of Science ®Google Scholar
• Bertrand D, Matignon M, Morel A, et al. Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv score > 2): a retrospective cohort study. Nephrol Dial Transplant. 2022; gfac178.
   PubMed Web of Science ®Google Scholar
• Budde K, Lehner F, Sommerer C, et al. ZEUS study investigators. five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: The randomized ZEUS study. Am J Transplant. 2015;15(1):119–128.
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009;9(5):1115–1123.
   PubMed Web of Science ®Google Scholar
• Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant. 2005;5(10):2496–2503.
   PubMed Web of Science ®Google Scholar
• Schena FP, Pascoe MD, Alberu J, et al., Sirolimus CONVERT trial study group: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2): 233–242.
   PubMed Web of Science ®Google Scholar
• Au E, Wong G, Chapman JR. Cancer in kidney transplant recipients. Nat Rev Nephrol. 2018;14(8):508–520.
   PubMed Web of Science ®Google Scholar
• D’Arcy ME, Castenson D, Lynch CF, et al. Risk of rare cancers among solid organ transplant recipients. JNCI. 2021;113(2):199–207.
   PubMedGoogle Scholar
• Rosales BM, De La Mata N, Vajdic CM, et al. Cancer mortality in kidney transplant recipients: An Australian And New Zealand population-based cohort study, 1980-2013. Int J Cancer. 2020;146(10):2703–2711.
   PubMed Web of Science ®Google Scholar
• Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–1227.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ma L, Xie Z, et al. Epidemiology of post-transplant malignancy in Chinese renal transplant recipients: a single-center experience and literature review. Med Oncol. 2014;31(7):32.
   PubMed Web of Science ®Google Scholar
• Lim W, Badve S, Wong G. Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer-a population cohort study. Oncotarget. 2017;8(44):77771–77782.
   PubMedGoogle Scholar
• Murray SL, Daly FE, O’Kelly P, et al. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients. Ren Fail. 2020;42(1):607–612.
   PubMed Web of Science ®Google Scholar
• Lim LM, Kung LF, Kuo MC, et al., Timing of mTORI usage and outcomes in kidney transplant recipients. Int J Med Sci. 2021;18(5): 1179–1184.
   PubMed Web of Science ®Google Scholar
• Badve SV, Pascoe EM, Burke M, et al. Mammalian target of rapamycin inhibitors and clinical outcomes in adult kidney transplant recipients. Clin J Am Soc Nephrol. 2016;11(10):1845–1855.
   PubMed Web of Science ®Google Scholar
• Cheung CY, Man MMK, Chak W, et al. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers. Oncotarget. 2017;8(27):44833–44841.
   PubMedGoogle Scholar
• Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801.
   PubMed Web of Science ®Google Scholar
• Murakami N, Mulvaney P, Danesh M, et al. Immune checkpoint inhibitors in solid organ transplant consortium. a multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021;100(1):196–205.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. Journal for ImmunoTherapy of Cancer. 2019;7(1):106.
   PubMed Web of Science ®Google Scholar
• Manohar S, Thongprayoon C, Cheungpasitporn W, et al. Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients. Kidney Int Rep. 2019;5(2):149–158.
   PubMed Web of Science ®Google Scholar
• Parker C, Kar S, Kirkpatrick PE. Eculizumab. Nat Rev Drug Discov. 2007;6(7):515–516.
   PubMed Web of Science ®Google Scholar
• Schmidtko J, Peine S, El-Housseini Y, et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61(2):289–299.
   PubMed Web of Science ®Google Scholar
• Avila Bernabeu AI, Cavero Escribano T, Cao Vilarino M. Atypical hemolytic uremic syndrome: New challenges in the complement blockage era. Nephron. 2020;144(11):537–549.
   PubMed Web of Science ®Google Scholar
• Zuber J, Le Quintrec M, Sberro-Soussan R, et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7(1):23–35.
   PubMed Web of Science ®Google Scholar
• Milan Manani S, Virzì GM, Ronco C. Long-term use of eculizumab in kidney transplant recipients. Kidney Int Rep. 2018;4(3):370–371.
   PubMed Web of Science ®Google Scholar
• Goodship TH, Cook HT, Fakhouri F, et al. Conference participants. atypical hemolytic uremic syndrome and C3 glomerulopathy: Conclusions from a “kidney disease: Improving global outcomes.” (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539–551.
   Google Scholar
• McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–737.
   PubMed Web of Science ®Google Scholar
• Plasse RA, Olson SW, Yuan CM, et al. Prophylactic or early use of eculizumab and graft survival in kidney transplant recipients with atypical hemolytic uremic syndrome in the United States: Research letter. Canadian Journal of Kidney Health and Disease. 2021;8:20543581211003763.
   Google Scholar
• Siedlecki AM, Isbel N, Vande W, et al. eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney International Reports. 2019;4(3):434–446.
   PubMed Web of Science ®Google Scholar
• Kant S, Bhalla A, Alasfar S, et al. Ten-year outcome of eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome– a single center experience. BMC Nephrol. 2020;21(1):189.
   PubMed Web of Science ®Google Scholar
• Legendre CM, Campistol JM, Feldkamp T. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: A pooled post hoc analysis. Transpl Int. 2017;30(12):1275–1283.
   PubMed Web of Science ®Google Scholar
• Le Quintrec M, Zuber J, Moulin B, et al., Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3): 663–675.
   PubMed Web of Science ®Google Scholar
• Ardissino G, Cresseri D, Tel F, et al. Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: Single-center experience with tailored eculizumab. J Nephrol. 2021;34(6):2027–2036.
   PubMed Web of Science ®Google Scholar
• Paglialonga F, Ardissino G, Consolo S, et al. Plasma-exchange in pediatric patients: a single-center experience. Minerva Pediatr. 2017;69(2):113–120.
   PubMed Web of Science ®Google Scholar
• Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337–3354. Comparative Study Multicenter Study.
   PubMed Web of Science ®Google Scholar
• van den Brand JA, Verhave JC, Adang EM, et al. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;1(32):115–122.
   Google Scholar
• ClinicalTrials.gov Identifier: NCT03663335
   Google Scholar
• Doberer K, Duerr M, Halloran PF. A randomized clinical trial of anti-IL 6 antibody clazakizumab in late antibody mediated kidney transplant rejection. J Am Soc Nephrol. 2021;32(3):708–722.
   PubMed Web of Science ®Google Scholar
• Daligault M, Bardy B, Noble J, et al. marginal impact of tocilizumab monotherapy on anti-HLA alloantibodies in highly sensitized kidney transplant candidates. Transplant Direct. 2021;7(5):e690.
   PubMed Web of Science ®Google Scholar
• Vo AA, Choi J, Kim I, et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. 2015;99(11):2356–2363.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Vescio R, and Toyoda M, et al. Daratumumab for treatment of antibody-mediated rejection in a kidney transplant recipient [abstract]. Am J Transplant. 2019;19(suppl 3). [cited 2022 Jul 18]. Available from: https://atcmeetingabstracts.com/abstract/daratumumab-for-treatment-of-antibody-mediated-rejection-in-a-kidney-transplant-recipient/.
   Web of Science ®Google Scholar
• Spica D, Junker T, Dickenmann M, et al. Daratumumab for treatment of antibody-mediated rejection after abo-incompatible kidney transplantation. Case Reports in Nephrology and Dialysis. 2019;9(3):149–157.
   PubMed Web of Science ®Google Scholar
• Banham GD, Flint SM, Torpey N, et al. Belimumab in kidney transplantation: An experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet. 2018;391(10140):2619–2630.
   PubMed Web of Science ®Google Scholar
• Viglietti D, Gosset C, Loupy A, et al. C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: A pilot study. Am J Transplant. 2016;16(5):1596–1603.
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Orandi BJ, Racusen L, et al. Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: Results of a randomized double-blind placebo-controlled pilot study. Am J Transplant. 2016;16(12):3468–3478.
   PubMed Web of Science ®Google Scholar
• Spasovski G, Masin-Spasovska J. How to improve the survival of the kidney transplant - list it only the pharmaceutical management? Expert Opin Pharmacother. 2014;15(7):905–908.
   PubMed Web of Science ®Google Scholar
• Viklicky O, Slatinska J, Novotny M, et al. Developments in immunosuppression. Curr Opin Organ Transplant. 2021;26(1):91–96.
   PubMed Web of Science ®Google Scholar
• Chadban S, Tedesco-Silva H. ATHENA: wisdom and warfare in defining the role of de novo mTOR inhibition in kidney transplantation. Kidney Int. 2019;96(1):27–30.
   PubMed Web of Science ®Google Scholar